Lee Hambright
Stock Analyst at Bernstein
(2.64)
# 1,923
Out of 4,810 analysts
22
Total ratings
68.75%
Success rate
8.46%
Average return
Main Sectors:
Stocks Rated by Lee Hambright
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MDT Medtronic | Maintains: Outperform | $96 → $97 | $84.22 | +15.17% | 2 | Nov 20, 2024 | |
| PODD Insulet | Initiates: Outperform | $300 | $255.47 | +17.43% | 1 | Nov 6, 2024 | |
| TNDM Tandem Diabetes Care | Initiates: Outperform | $42 | $17.03 | +146.62% | 1 | Nov 6, 2024 | |
| DXCM DexCom | Maintains: Outperform | $82 → $86 | $67.39 | +27.62% | 2 | Oct 25, 2024 | |
| BSX Boston Scientific | Maintains: Outperform | $92 → $100 | $94.27 | +6.08% | 1 | Oct 24, 2024 | |
| ABT Abbott Laboratories | Maintains: Outperform | $133 → $138 | $127.96 | +7.85% | 2 | Oct 17, 2024 | |
| ISRG Intuitive Surgical | Maintains: Outperform | $350 → $365 | $490.13 | -25.53% | 2 | May 31, 2023 | |
| ZBH Zimmer Biomet Holdings | Maintains: Market Perform | $136 → $152 | $101.97 | +49.06% | 1 | May 3, 2023 | |
| JNJ Johnson & Johnson | Downgrades: Market Perform | $183 | $154.36 | +18.55% | 4 | Mar 16, 2022 | |
| SYK Stryker | Upgrades: Outperform | $288 → $295 | $353.42 | -16.53% | 3 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $132 → $135 | $69.87 | +93.22% | 3 | Mar 16, 2022 |
Medtronic
Nov 20, 2024
Maintains: Outperform
Price Target: $96 → $97
Current: $84.22
Upside: +15.17%
Insulet
Nov 6, 2024
Initiates: Outperform
Price Target: $300
Current: $255.47
Upside: +17.43%
Tandem Diabetes Care
Nov 6, 2024
Initiates: Outperform
Price Target: $42
Current: $17.03
Upside: +146.62%
DexCom
Oct 25, 2024
Maintains: Outperform
Price Target: $82 → $86
Current: $67.39
Upside: +27.62%
Boston Scientific
Oct 24, 2024
Maintains: Outperform
Price Target: $92 → $100
Current: $94.27
Upside: +6.08%
Abbott Laboratories
Oct 17, 2024
Maintains: Outperform
Price Target: $133 → $138
Current: $127.96
Upside: +7.85%
Intuitive Surgical
May 31, 2023
Maintains: Outperform
Price Target: $350 → $365
Current: $490.13
Upside: -25.53%
Zimmer Biomet Holdings
May 3, 2023
Maintains: Market Perform
Price Target: $136 → $152
Current: $101.97
Upside: +49.06%
Johnson & Johnson
Mar 16, 2022
Downgrades: Market Perform
Price Target: $183
Current: $154.36
Upside: +18.55%
Stryker
Mar 16, 2022
Upgrades: Outperform
Price Target: $288 → $295
Current: $353.42
Upside: -16.53%
Mar 16, 2022
Upgrades: Outperform
Price Target: $132 → $135
Current: $69.87
Upside: +93.22%